Physician profile
Dina Bolden
NPI 1962721894
$2,209.93
in general payments reported to CMS, 2019-2025
7 companies · $650 in 2025
The $650 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $424 · 2023: $676 · 2024: $325 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,147.77 | 2021-2025 | Fintepla |
| Neurelis, INC. | $399.23 | 2023-2025 | Valtoco |
| Immedica Pharma US, INC. | $227.61 | 2022-2023 | |
| Ceribell, INC. | $119.84 | 2023 | Ceribell Rapid Response |
| Jazz Pharmaceuticals INC. | $116.00 | 2022 | |
| Sk Life Science, INC. | $110.09 | 2023-2024 | |
| Biomarin Pharmaceutical INC. | $89.39 | 2023 | Brineura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Bolden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.